Completed PHASE4 INTERVENTIONAL NCT00204347

Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder

Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS)

Sponsor: Janssen Pharmaceutica

Conditions Borderline Personality Disorder

Interventions risperidone

Updated 6 times since 2017 Last updated: Jun 8, 2021 Started: Jul 31, 2003 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00204347, this PHASE4 trial focuses on Borderline Personality Disorder and remains completed. Sponsored by Janssen Pharmaceutica, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Sep 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutica
University of Alabama at Birmingham

Data source: University of Alabama at Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United States